文献速递泌尿生殖与妇科肿瘤放疗

宫颈癌同步放化疗期间局部与全身肿瘤免疫微环境的动态变化:一项前瞻性临床试验

The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-03-10

该单中心前瞻性临床试验纳入55例IIA–IVA期宫颈癌患者,在同步放化疗(CCRT)前、中、后采集肿瘤组织与外周血单个核细胞(PBMC),分析淋巴细胞亚群、PD-1/PD-L1表达及T细胞受体(TCR)库变化。结果显示CCRT降低CD4+、CD8+ T细胞数量、PD-L1阳性细胞比例及TCR多样性,且CCRT前PBMC中较高的TCR多样性与更优的30个月无进展生存和总生存相关,提示免疫检查点抑制剂可能宜在CCRT前给予。

要点

  • CCRT降低外周血CD4+和PD-1+ T细胞频率,抑制性调节性T细胞增加。
  • 肿瘤组织CD4+、CD8+ T细胞减少,PD-L1阳性细胞中位比例由78.1%降至49.8%。
  • CCRT前PBMC TCR多样性高者30个月PFS和OS更优。

核心结论

  • 宫颈癌CCRT降低CD4+和CD8+ T淋巴细胞群、PD-1/PD-L1表达及TCR多样性,提示CCRT可能抑制免疫激活。
  • CCRT前PBMC中较高的TCR多样性与更好的生存和预后相关,提示免疫检查点抑制剂在CCRT前给予可能比在CCRT期间或之后更有效。

研究设计与样本

  • 所有患者接受顺铂同步外照射放疗联合高剂量率近距离放疗。
  • 在CCRT前、中、后采集肿瘤组织与外周血单个核细胞(PBMC),分析淋巴细胞亚群、PD-1/PD-L1表达及TCR库变化。

主要发现

  • PBMC中CD4+和PD-1+ T细胞频率在CCRT开始后下降,而抑制性调节性T细胞增加。
  • 肿瘤组织中CCRT降低CD4+和CD8+ T细胞数量,PD-L1阳性细胞中位比例从78.1%降至49.8%。
  • 以独特克隆数计,PBMC的TCR在CCRT前比CCRT后呈现更大多样性。
  • CCRT前PBMC中更大的TCR多样性与更优的30个月无进展生存相关(HR 0.12;95%CI 0.04-0.39;P=.001)。
  • CCRT前PBMC中更大的TCR多样性也与更优的总生存相关(HR 0.17;95%CI 0.04-0.68;P=.004)。

临床怎么用

  • 结果提示对宫颈癌患者考虑免疫检查点抑制剂时,CCRT前给予可能比CCRT期间或之后更有效。
  • CCRT前PBMC的TCR多样性或可作为预测生存预后的潜在免疫指标。

局限性

  • 单中心前瞻性临床试验,样本量为55例,统计效力有限。
  • 中位随访32.1个月,长期生存与免疫动态变化仍需更长随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This work assessed local and systemic alternations of the tumor immune microenvironment during concurrent chemoradiation therapy (CCRT) of local advanced cervical cancer to estimate the optimal timing for immune therapy in relation to CCRT. METHODS AND MATERIALS: In this single-center prospective clinical trial, 55 patients with stage IIA through IVA cervical cancer were enrolled between December 2016 and November 2017. The median follow-up was 32.1 months. All patients received cisplatin concurrently with external beam radiation therapy combined with high-dose-rate brachytherapy. Tumor tissues and peripheral blood mononuclear cells (PBMCs) were collected before, during and after CCRT. We analyzed the changes in lymphocyte subpopulations, programmed death-1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression, and the T cell receptor (TCR) repertoire that occurred throughout CCRT. RESULTS: The frequencies of CD4+ and PD-1+ T cells in PBMCs decreased after the start of CCRT, whereas that of inhibitory regulatory T cells increased. In the tumor tissues, CCRT decreased the numbers of CD4+ and CD8+ T cells and reduced the median percentage of positive cells expressing PD-L1 from 78.1% to 49.8%. As indicated by the numbers of unique clones, the TCRs of PBMCs exhibited greater diversity before CCRT than after CCRT. Greater TCR diversity in PBMCs before CCRT was associated with superior 30-month progression-free survival (hazard ratio [HR], 0.12; 95% confidence interval [CI], 0.04-0.39; P = .001) and overall survival (HR, 0.17; 95% CI, 0.04-0.68; P = .004). CONCLUSIONS: CCRT for cervical cancer altered the tumor immune microenvironment by reducing CD4+ and CD8+ T lymphocyte populations, PD-1/PD-L1 expression, and TCR diversity. Higher TCR diversity in PBMCs before CCRT resulted in better survival and prognosis, indicating that CCRT might inhibit immune activation. Our results suggest that it might be more effective to administer immune checkpoint inhibitors before CCRT of cervical cancer rather than during or after CCRT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Li R, Liu Y, Yin R, et al. The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial. Int J Radiat Oncol Biol Phys. 2021. PMID: 33713744. doi:10.1016/j.ijrobp.2021.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。